Skip to main content

Advertisement

SpringerLink
Log in

Innovation and Future Perspectives in the Treatment of Colorectal Liver Metastases

  • SSAT Summary
  • Published:
Journal of Gastrointestinal Surgery

Abstract

Technological advances and investigation into tumor biology have enhanced treatments of patients with colorectal liver metastases (CLM). This article briefly summarizes paradigm shifts in treatments of this disease in the following 4 sections. (1) Small metastases: The treatment of multiple and small CLM has evolved from anatomic resection to parenchyma-sparing hepatectomy. Survival after parenchyma-sparing hepatectomy was similar to or better than anatomic resection. The use of preoperative chemotherapy may cause tumor disappearance. However, the use of fiducial markers may aid in intraoperative localization. Post-resection completion ablation is a new useful treatment concept. It was defined as percutaneous ablation under cross-sectional imaging guidance to eradicate CLM which were intentionally unresected during latest surgery. (2) Bilateral (bilobar) metastases: Two-stage hepatectomy (TSH) is a well-established approach for treating multiple bilateral CLM. The use of hybrid operating room accelerates this sequence because it allows first-stage hepatectomy, portal vein embolization, and computed tomography in one hospitalization. This accelerated TSH sequence enables the second-stage hepatectomy within 4 weeks compared to 8 weeks using conventional TSH sequence. (3) Synchronous lung metastases: For patients with synchronous liver and lung metastases, simultaneous surgical approach is feasible. Specifically, a transdiaphragmatic approach enables simultaneous resection of liver and lung metastases via one abdominal incision. (4) Multiple mutation: Somatic gene mutation testing is increasingly used to evaluate tumor biology. Mutations in TP53, RAS, and SMAD4 affect prognosis through three different signaling pathways of colorectal carcinogenesis. This information can be used to change clinical decision-making regarding surveillance intensity and treatments for liver recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Mise Y, Aloia TA, Brudvik KW, et al. Parenchymal-sparing hepatectomy in colorectal liver metastasis improves salvageability and survival. Ann Surg 2016; 263:146–152.

    Article  Google Scholar 

  2. Sui CJ, Cao L, Li B, et al. Anatomical versus nonanatomical resection of colorectal liver metastases: a meta-analysis. Int J Colorectal Dis 2012; 27:939–946.

    Article  Google Scholar 

  3. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. The Lancet 2008; 371:1007–1016.

    Article  CAS  Google Scholar 

  4. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. The Lancet Oncology 2013; 14:1208–1215.

    Article  CAS  Google Scholar 

  5. Passot G, Odisio BC, Zorzi D, et al. Eradication of Missing Liver Metastases After Fiducial Placement. J Gastrointest Surg 2016; 20:1173–1178.

    Article  Google Scholar 

  6. Abdalla EK, Vauthey J-N, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239:818–827.

    Article  Google Scholar 

  7. Shady W, Petre EN, Gonen M, et al. Percutaneous radiofrequency ablation of colorectal cancer liver metastases: factors affecting outcomes--a 10-year experience at a single center. Radiology 2016; 278:601–611.

    Article  Google Scholar 

  8. Calandri M, Yamashita S, Gazzera C, et al. Ablation of colorectal liver metastasis: Interaction of ablation margins and RAS mutation profiling on local tumour progression-free survival. Eur Radiol 2018; 28:2727–2734.

    Article  Google Scholar 

  9. Odisio BC, Yamashita S, Huang SY, et al. Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status. Br J Surg 2017; 104:760–768.

    Article  CAS  Google Scholar 

  10. Odisio BC, Yamashita S, Frota L, et al. Planned treatment of advanced metastatic disease with completion ablation after hepatic resection. J Gastrointest Surg 2017; 21:628–635.

    Article  Google Scholar 

  11. Kawaguchi Y, Lillemoe HA, Vauthey JN. Gene mutation and surgical technique: Suggestion or more?, Surg Oncol 2019:https://doi.org/10.1016/j.suronc.2019.1007.1004.

  12. Jiang BB, Yan K, Zhang ZY, et al. The value of KRAS gene status in predicting local tumor progression of colorectal liver metastases following radiofrequency ablation. Int J Hyperthermia 2019; 36:211–219.

    PubMed  Google Scholar 

  13. Margonis GA, Sasaki K, Andreatos N, et al. KRAS mutation status dictates optimal surgical margin width in patients undergoing resection of colorectal liver metastases. Ann Surg Oncol 2017; 24:264–271.

    Article  Google Scholar 

  14. Brudvik KW, Mise Y, Chung MH, et al. RAS mutation predicts positive resection margins and narrower resection margins in patients undergoing resection of colorectal liver metastases. Ann Surg Oncol 2016; 23:2635–2643.

    Article  Google Scholar 

  15. Puijk RS, Ruarus AH, Vroomen L, et al. Colorectal liver metastases: surgery versus thermal ablation (COLLISION) - a phase III single-blind prospective randomized controlled trial. BMC Cancer 2018; 18:821.

    Article  Google Scholar 

  16. Kawaguchi Y, Lillemoe HA, Vauthey JN. Dealing with an insufficient future liver remnant: Portal vein embolization and two-stage hepatectomy. J Surg Oncol 2019; 119:594–603.

    Article  Google Scholar 

  17. Odisio BC, Simoneau E, Holmes AA, et al. Fast-Track Two-Stage hepatectomy using a hybrid interventional radiology/operating suite as alternative option to associated liver partition and portal vein ligation for staged hepatectomy procedure. J Am Coll Surg 2018; 227:e5-e10.

    Article  Google Scholar 

  18. Lillemoe HA, Kawaguchi Y, Passot G, et al. Surgical resection for recurrence after two-stage hepatectomy for colorectal liver metastases is feasible, is safe, and improves survival. J Gastrointest Surg 2018; 23:84–92.

    Article  Google Scholar 

  19. Mise Y, Mehran RJ, Aloia TA, Vauthey JN. Simultaneous lung resection via a transdiaphragmatic approach in patients undergoing liver resection for synchronous liver and lung metastases. Surgery 2014; 156:1197–1203.

    Article  Google Scholar 

  20. Mise Y, Kopetz S, Mehran RJ, et al. Is complete liver resection without resection of synchronous lung metastases justified? Ann Surg Oncol 2015; 22:1585–1592.

    Article  Google Scholar 

  21. Chun YS, Mehran RJ, Tzeng C-WD, et al. LUNA: A randomized phase II trial of liver resection plus chemotherapy or chemotherapy alone in patients with unresectable lung and resectable liver metastases from colorectal adenocarcinoma. J Clin Oncol 2017; 35:TPS3625-TPS3625.

    Article  Google Scholar 

  22. Chun YS, Passot G, Yamashita S, et al. Deleterious effect of RAS and evolutionary high-risk TP53 double mutation in colorectal liver metastases. Ann Surg 2017; 269:917–923.

    Article  Google Scholar 

  23. Kawaguchi Y, Lillemoe HA, Panettieri E, et al. Conditional recurrence-free survival after resection of colorectal liver metastases: Persistent deleterious association with RAS and TP53 Co-Mutation. J Am Coll Surg 2019:https://doi.org/10.1016/j.jamcollsurg.2019.1004.1027.

  24. Kawaguchi Y, Kopetz S, Newhook TE, et al. Mutation status of RAS, TP53, and SMAD4 is superior to mutation status of RAS alone for predicting prognosis after resection of colorectal liver metastases. Clin Cancer Res 2019: https://doi.org/10.1158/1078-0432.CCR-1119-0863. [Epub ahead of print].

  25. Mizuno T, Cloyd JM, Vicente D, et al. SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases. Eur J Surg Oncol 2018; 44:684–692.

    Article  Google Scholar 

Download references

Acknowledgments

The authors thank Ms. Ruth Haynes for administrative support in the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1484, Houston, TX, 77030, USA

    Jean-Nicolas Vauthey & Yoshikuni Kawaguchi

Authors
  1. Jean-Nicolas Vauthey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshikuni Kawaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-Nicolas Vauthey.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vauthey, JN., Kawaguchi, Y. Innovation and Future Perspectives in the Treatment of Colorectal Liver Metastases. J Gastrointest Surg 24, 492–496 (2020). https://doi.org/10.1007/s11605-019-04399-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11605-019-04399-3

Keywords

Search

Navigation